Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 10/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | TEC | P42680 | 1/20 | 0.32 |
| ▸ | TXK | P42681 | 1/20 | 0.32 |
| ▸ | BMX | P51813 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709216 | 0.92 | BRAF (0.38) | BRAFBTKFPR2METMAP3K7 | |
| SCHEMBL15054097 | 0.91 | BRAF (0.38) | BRAFBTKMETMAP3K7JAK2 | |
| Hydrochloric Acid SCHEMBL15053595 | 0.91 | BRAF (0.37) | BRAFBTKMETMAP3K7JAK2 | |
| SCHEMBL15053898 | 0.91 | KDR (0.41) | BRAFBTKKDRFLT3 | |
| SCHEMBL15053943 | 0.90 | BTK (0.41) | BRAFBTKMETITKCYP1A2 | |
| SCHEMBL15053740 | 0.89 | BRAF (0.48) | BRAFKDRCYP2C9 | |
| SCHEMBL15052967 | 0.89 | HTR2A (0.39) | BRAFCYP1A2CYP3A4SHMT2 | |
| SCHEMBL15054385 | 0.89 | STING1 (0.41) | BRAFBTKMAP3K7ITKCYP1A2 | |
| SCHEMBL15053103 | 0.89 | MAP3K7 (0.39) | BRAFBTKFPR2METMAP3K7 | |
| SCHEMBL15053476 | 0.89 | KDR (0.39) | BRAFBTKMETMAP3K7KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | BRAF 90/4885BTK 337/4885FPR2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.